U.S. Markets open in 8 hrs 15 mins
  • S&P Futures

    4,361.25
    +12.25 (+0.28%)
     
  • Dow Futures

    34,240.00
    +55.00 (+0.16%)
     
  • Nasdaq Futures

    14,222.25
    +81.50 (+0.58%)
     
  • Russell 2000 Futures

    2,002.50
    +1.20 (+0.06%)
     
  • Crude Oil

    85.30
    -0.30 (-0.35%)
     
  • Gold

    1,848.30
    -4.20 (-0.23%)
     
  • Silver

    23.78
    -0.12 (-0.49%)
     
  • EUR/USD

    1.1308
    +0.0003 (+0.0226%)
     
  • 10-Yr Bond

    1.7830
    0.0000 (0.00%)
     
  • Vix

    31.16
    +2.31 (+8.01%)
     
  • GBP/USD

    1.3513
    +0.0007 (+0.0513%)
     
  • USD/JPY

    113.8820
    +0.0160 (+0.0141%)
     
  • BTC-USD

    37,649.13
    +1,578.97 (+4.38%)
     
  • CMC Crypto 200

    854.92
    +44.32 (+5.47%)
     
  • FTSE 100

    7,371.46
    -122.67 (-1.64%)
     
  • Nikkei 225

    27,013.69
    -117.65 (-0.43%)
     

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • SWTX

STAMFORD, Conn., June 01, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8th at 3:00PM ET.

To access the live webcast please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology portfolio of small molecule product candidates and is advancing two potentially registrational clinical trials in rare tumor types as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to expand its portfolio to create more solutions for patients with cancer. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.

Contact:
Kim Diamond
Phone: 203-561-1646
Email: kdiamond@springworkstx.com